Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|May 10, 2024
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignanciesPieterjan Vanclooster, Sofie Seghers, Hans Prenen
Cancers|August 10, 2024
Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal CancerDenise van der Graaff, Sofie Seghers, Pieterjan Vanclooster, et al.
Chemsuschem|March 27, 2018
Enhancing Zeolite Performance by Catalyst Shaping in a Mesoscale Continuous-Flow Diels-Alder ProcessSofie Seghers, Jasper Lefevere, Steven Mullens, et al.
Chemsuschem|May 12, 2018
Design of a Mesoscale Continuous-Flow Route toward Lithiated MethoxyalleneSofie Seghers, Thomas S A Heugebaert, Matthias Moens, et al.
Cancer Treatment Reviews|April 21, 2023
Immediate hypersensitivity reactions to antineoplastic agents - A practical guide for the oncologistSofie Seghers, Laure-Anne Teuwen, Michiel Beyens, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|October 25, 2019
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trialsOmar Najim, Sofie Seghers, Laurine Sergoynne, et al.
Critical Reviews in Oncology/Hematology|February 4, 2024
A systematic review of patient-derived tumor organoids generation from malignant effusionsSofie Seghers, Maxim Le Compte, Jeroen M H Hendriks, et al.
JCO Oncology Practice|February 27, 2025
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022Sofie Seghers, Pablo Mandó, Marc Eid, et al.
Communications Biology|December 3, 2024
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assaysChristophe Deben, Edgar Cardenas De La Hoz, Felicia Rodrigues Fortes, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 22, 2024
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibitionChristophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, et al.
Pageof 2